Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial
| Autor: | Saoussen Ben Abdallah, Yosra Mhalla, Imen Trabelsi, Adel Sekma, Rim Youssef, Khaoula Bel Haj Ali, Houda Ben Soltane, Hajer Yacoubi, Mohamed Amine Msolli, Nejla Stambouli, Kaouthar Beltaief, Mohamed Habib Grissa, Meriem Khrouf, Zied Mezgar, Chawki Loussaief, Wahid Bouida, Rabie Razgallah, Karima Hezbri, Asma Belguith, Naouel Belkacem, Zohra Dridi, Hamdi Boubaker, Riadh Boukef, Semir Nouira |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Clinical Infectious Diseases. 76:185-191 |
| ISSN: | 1537-6591 1058-4838 0521-2480 |
| DOI: | 10.1093/cid/ciac807 |
| Popis: | Background Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection. Methods We conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial. Patients who were tested positive for COVID-19 without end-organ failure were randomized to oral zinc (n = 231) or matching placebo (n = 239) for 15 days. The primary combined outcome was death due to COVID-19 or intensive care unit (ICU) admission ≤30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19–related hospitalization for outpatients. Results 190 patients (40.4%) were ambulatory and 280 patients (59.6%) were hospitalized. Mortality at 30 days was 6.5% in the zinc group and 9.2% in the placebo group (OR: .68; 95% CI .34–1.35); ICU admission rates were, respectively, 5.2% and 11.3% (OR: .43; 95% CI .21–.87). Combined outcome was lower in the zinc group versus the placebo group (OR: .58; 95% CI .33–.99). Consistent results were observed in prespecified subgroups of patients aged Conclusions Our results showed that, in COVID-19 patients, oral zinc can decrease 30-day death, ICU admission rate and can shorten symptom duration. Clinical Trials Registration. ClinicalTrials.gov, NCT05212480. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|